Literature DB >> 16834537

Interrogating genomes with combinatorial artificial transcription factor libraries: asking zinc finger questions.

Adriana Beltran1, Yanzheng Liu, Shaunak Parikh, Brenda Temple, Pilar Blancafort.   

Abstract

Artificial transcription factors (ATFs) are proteins designed to specifically bind and regulate genes. Because of their DNA-binding selectivity and modular organization, arrays of zinc finger (ZF) domains have traditionally been used to build the ATF's DNA-binding domains. ATFs have been designed and constructed to regulate a variety of therapeutic targets. Recently, novel combinatorial technologies have been developed to induce expression of any gene of interest or to modify cellular phenotypes. Large repertoires of ATFs have been generated by recombination of all available sequence-specific ZF lexicons. These libraries comprise millions of ATFs with unique DNA-binding specificities. The ATFs are produced by combinatorial assembly of three- and six-ZF building blocks and are linked to activator or repressor domains. Upon delivery into a cell population, any gene in the human genome can potentially be regulated. ATF library members generate genome-wide, experimental perturbations of gene expression, resulting in a phenotypically diverse population, or cellular library. A variety of phenotypic screenings can be applied to select for cells exhibiting a phenotype of interest. The ATFs are then used as genetic probes to identify the targeted genes responsible for the phenotypic switch. In this review we will summarize several applications of ATF library screenings in gene discovery, biotechnology, and disease therapeutics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16834537     DOI: 10.1089/adt.2006.4.317

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  8 in total

Review 1.  Insights from genomic profiling of transcription factors.

Authors:  Peggy J Farnham
Journal:  Nat Rev Genet       Date:  2009-08-11       Impact factor: 53.242

Review 2.  Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules.

Authors:  Pilar Blancafort; Jian Jin; Stephen Frye
Journal:  Mol Pharmacol       Date:  2012-11-13       Impact factor: 4.436

3.  Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors.

Authors:  Haydee Lara; Yuhua Wang; Adriana S Beltran; Karla Juárez-Moreno; Xinni Yuan; Sumie Kato; Andrea V Leisewitz; Mauricio Cuello Fredes; Alexei F Licea; Denise C Connolly; Leaf Huang; Pilar Blancafort
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

4.  Assessing the potential of mutational strategies to elicit new phenotypes in industrial strains.

Authors:  Daniel Klein-Marcuschamer; Gregory Stephanopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-05       Impact factor: 11.205

5.  Suppression of breast tumor growth and metastasis by an engineered transcription factor.

Authors:  Adriana S Beltran; Angela Russo; Haydee Lara; Cheng Fan; Paul M Lizardi; Pilar Blancafort
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

6.  Zinc Finger Artificial Transcription Factor-Mediated Chloroplast Genome Interrogation in Arabidopsis thaliana.

Authors:  Niels van Tol; Gema Flores Andaluz; Hendrika A C F Leeggangers; M Reza Roushan; Paul J J Hooykaas; Bert J van der Zaal
Journal:  Plant Cell Physiol       Date:  2019-02-01       Impact factor: 4.927

7.  Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer.

Authors:  Sabine Stolzenburg; Marianne G Rots; Adriana S Beltran; Ashley G Rivenbark; Xinni Yuan; Haili Qian; Brian D Strahl; Pilar Blancafort
Journal:  Nucleic Acids Res       Date:  2012-05-04       Impact factor: 16.971

8.  Utrophin up-regulation by an artificial transcription factor in transgenic mice.

Authors:  Elisabetta Mattei; Nicoletta Corbi; Maria Grazia Di Certo; Georgios Strimpakos; Cinzia Severini; Annalisa Onori; Agata Desantis; Valentina Libri; Serena Buontempo; Aristide Floridi; Maurizio Fanciulli; Dilair Baban; Kay E Davies; Claudio Passananti
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.